Search results
Results from the WOW.Com Content Network
The 2010 DePuy Hip Replacement Recall was instituted when DePuy Orthopaedics, Inc., a division of Johnson and Johnson, recalled its ASR XL Acetabular metal-on-metal hip replacement system on August 24, 2010. [1] [2]
For 129 years, New Brunswick has served as the headquarters of J&J, America’s seventh most valuable public company. With consumer products from Band-Aids to baby powder, Neutrogena to Rogaine, Listerine to Visine, Aveeno to Tylenol and Sudafed to Splenda, Johnson & Johnson is the biggest and, according to multiple surveys, most admired ...
In many other countries, DePuy operates as a brand under the Johnson & Johnson Medical organization. [1] DePuy is currently the subject of more than 11,000 lawsuits related to its recall of faulty hip replacement systems, which lawyers and industry analysts estimate will cost parent company Johnson & Johnson billions of dollars to resolve. [2]
June 11, 2024 at 2:34 PM. By Jonathan Stempel. NEW YORK (Reuters) - Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its ...
The Supreme Court on Thursday rejected a nationwide settlement with OxyContin maker Purdue Pharma that would have shielded members of the Sackler family who own the company from civil lawsuits ...
Johnson & Johnson. / 40.49861°N 74.44361°W / 40.49861; -74.44361. Johnson & Johnson ( J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones ...
June 19, 2024 at 10:52 PM. The U.S. Food and Drug Administration (FDA) sent a warning letter to Dollar Tree, Inc. last week after an investigation revealed the company failed to remove a children ...
Two other allegedly faulty J&J products targeted by the plaintiffs lawyers were a device called a transvaginal mesh patch and an artificial hip implant. Suits involving these two products would soon end up competing with Risperdal for claims on the company’s reputation and treasury. Johnson & Johnson seemed to take the threats in stride.